



The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

Andrea Botticelli^{1,2}, Chiara Cremolini³, Simone Scagnoli^{1,2}, Mauro Biffoni⁴, Sara Lonardi⁵, Lorenzo Fornaro⁶, Valentina Guarneri^{5,7}, Ugo De Giorgi⁸, Paolo Antonio Ascierto⁹, Giovanni Blandino¹⁰, Giulia D'Amati^{1,2}, Massimo Aglietta¹¹, Pierfranco Conte^{12,13}, Edoardo Crimini^{14,15}, Maurizio Ceracchi^{16,17}, Simona Pisegna^{18,19}, Sofia Verkhovskaia²⁰, Roberto Bordonaro²¹, Sergio Bracarda²², Giovanni Butturini²³, Lucia Del Mastro^{24,25}, Andrea DeCensi²⁶, Agnese Fabbri²⁷, Elisabetta Fenocchio¹¹, Stefania Gori²⁸, Giulio Metro²⁹, Annamaria Pessino³⁰, Daniele Pozzessere³¹, Fabio Puglisi^{32,33}, Stefano Tamberi³⁴, Alberto Zambelli^{35,36}, Donatella Marino³⁷, Ettore Capoluongo³⁸, Federico Cappuzzo³⁹, Bruna Cerbelli^{1,2}, Giuseppe Giannini⁴⁰, Umberto Malapelle⁴¹, Federica Mazzuca^{19,42}, Marianna Nuti¹⁸, Giancarlo Pruneri⁴³, Maurizio Simmaco^{44,45}, Lidia Strigari⁴⁶, Giuseppe Tonini^{47,48}, Nello Martini⁴⁹, Giuseppe Curigliano^{14,15}, and Paolo Marchetti²⁰

ABSTRACT

Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial.

Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one.

Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%)

biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups.

Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts.

See related commentary by Saldanha and Siu, p. 7

Introduction

Genomic profiling has revolutionized cancer treatment by enabling personalized medicine approaches (1). By identifying specific genetic mutations and variations within a tumor, clinicians can tailor treatments to target these alterations, thereby increasing the efficacy of therapies and minimizing adverse effects. One significant

advantage is the ability to predict patient response to certain drugs, allowing for more precise and effective treatment plans (2). Additionally, genetic profiling can identify potential resistance mechanisms, enabling the adjustment of therapeutic strategies to overcome these challenges (3). This approach improves patient outcomes and contributes to the development of novel targeted therapies, advancing the field of oncology (4).

¹Department of Radiological, Oncological and Pathological Sciences, Sapienza Università di Roma, Rome, Italy. ²AOU Policlinico Umberto I, Rome, Italy. ³Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. ⁴Department of Oncology and Molecular Medicine, Italian National Institute of Health (ISS), Rome, Italy. ⁵Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. ⁶Division of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa University Hospital, Pisa, Italy. ⁷Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padua, Italy. ⁸IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. ⁹Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy. ¹⁰Translational Oncology Research Unit, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy. ¹¹Candiolo Cancer Institute FPO Istituto di Ricovero e Cura a Carattere

Scientifico Candiolo, Candiolo, Italy. ¹²S. Camillo Hospital IRCCS, Venice, Italy. ¹³Fondazione Periplo, Genoa, Italy. ¹⁴Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy. ¹⁵Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. ¹⁶CMV STAT S.r.l., Rome, Italy. ¹⁷STS, Rome, Italy. ¹⁸Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. ¹⁹Oncology Unit, Azienda Ospedaliera Universitaria Sant' Andrea, Rome, Italy. ²⁰Department of Oncology, IDI-IRCCS, Rome, Italy. ²¹Medical Oncology Unit -ARNAS Garibaldi, Catania, Italy. ²²Oncologia Medica Traslazionale, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy. ²³Hepatopancreatobiliary (HPB) Surgery, Pederzoli Hospital, Verona, Italy. ²⁴IRCCS Ospedale Policlinico San Martino, UO clinica Oncologia Medica, Genoa, Italy. ²⁵Department of Internal Medicine and Medical Specialties (DIMI), Università di Genova, Genoa, Italy.

Translational Relevance

This exploratory analysis indicates that the combined use of tissue and liquid biopsies may enhance the detection of actionable alterations and be associated with improved survival outcomes in patients with advanced solid tumors receiving matched therapies. These findings highlight the potential relevance of integrating both biopsy modalities in the context of precision oncology.

Recently, liquid biopsy profiling has emerged as a forefront technology in cancer diagnostics, showcasing distinct advantages compared with traditional solid biopsy profiling (5).

Genomic profiling based on solid biopsies provides a detailed histologic and molecular analysis of the tumor, allowing for precise characterization and diagnosis. It is crucial for determining the tumor type, grade, and specific genetic mutations, which are critical for guiding treatment decisions and offering a comprehensive view of the tumor's cellular makeup, aiding in the identification of potential therapeutic targets (6). Although the advantages of solid biopsy are significant, it remains an invasive procedure that requires surgical extraction or biopsy of tissue, which can be associated with risks such as bleeding, infection, and patient discomfort (7). In addition, tissue biopsy may fail to capture tumor heterogeneity, as it samples only a specific area and may miss mutations present in other tumor regions or metastatic sites. Furthermore, it is limited in its ability to provide real-time information on treatment response and disease progression (8).

On the other hand, a liquid biopsy is minimally invasive, reducing patient discomfort and the risk of complications (9). It enables real-time monitoring of treatment response and detection of molecular changes that may indicate resistance to therapy while providing a dynamic snapshot of the disease. Liquid biopsies capture genetic information from multiple tumor sites, which can be particularly useful for tracking metastatic cancer (10, 11). However, liquid biopsy may not detect mutations from tumors that do not shed enough cells or DNA into the bloodstream, potentially missing critical genetic information (12). It is

limited in its ability to provide detailed histologic information, which is essential for certain diagnostic and treatment decisions. The technology and interpretation of liquid biopsy results are still evolving, and there may be variability in the accuracy and reliability of the tests (5, 13).

Integrating liquid and solid biopsy profiling offers a comprehensive approach to tumor characterization, addressing tumor heterogeneity and enhancing the precision of cancer diagnostics and treatment. By combining both approaches, clinicians can obtain a more extensive view of the tumor's genetic makeup and its dynamic changes over time. This integrated approach enhances the ability to tailor treatments to individual patients, ultimately improving clinical outcomes and driving forward the advancements in precision oncology (14).

The complexity of interpreting genomic results from liquid and solid biopsies presents numerous challenges for clinicians, who often face difficulties in analyzing such data effectively (15). In this context, molecular tumor boards (MTB) are emerging as a robust support system for clinicians, providing valuable insights into interpreting complex genomic findings (16) within the mutational model.

The ROME trial (Clinical Trials Registry, NCT04591431) was a multicentric, prospective, randomized phase II study that used the MTB discussion of extensive genomic profiling as a key milestone in driving treatment decisions based on molecular profiling of solid and liquid biopsies. In this study, 1,794 patients with solid tumors who had undergone at least one but no more than two lines of therapy were screened. Patients were required to undergo genomic profiling on both solid and liquid biopsies. If alterations were found that could be discussed, the cases were brought before the MTB. If actionable alterations emerged during the MTB discussion, patients were randomized to receive either a tailored treatment (TT) or the standard-of-care (SoC) chosen by the clinician presenting the case (17). Representative table of the overall population is reported in Supplementary Table S1. Matching of TT with the altered pathways is illustrated in Supplementary Table S2.

In this exploratory analysis, we evaluated the concordance of genomic profiling from both solid and liquid biopsies in patients enrolled in the ROME trial. We analyzed how this concordance affected patient outcomes. By examining the alignment between the genomic data from different biopsy types and the subsequent clinical decisions, we aimed to assess its influence on treatment efficacy.

²⁶Department of Medicine and Medical Oncology Unit E.O. Ospedali Galliera, Genoa, Italy. ²⁷Department of Oncology, Central Hospital of Santa Rosa-Belcolle, Viterbo, Italy. ²⁸Department of Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. ²⁹Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy. ³⁰Oncologia medica 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ³¹Medical Oncology Unit, Nuovo Ospedale di Prato-Santo Stefano, Azienda USL Toscana Centro, Prato, Italy. ³²Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy. ³³Department of Medicine, University of Udine, Udine, Italy. ³⁴Oncology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy. ³⁵Oncology Unit ASST Papa Giovanni XXIII, Bergamo, Italy. ³⁶Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy. ³⁷Department of Oncology, Ordine Mauriziano Hospital, Turin, Italy. ³⁸Dipartimento Di Eccellenza In Medicina Molecolare E Biotecnologie Mediche, Università Federico II, Naples, Italy. ³⁹Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ⁴⁰Department of Molecular Medicine, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia, Fondazione Cenci-Bolognetti, Rome, Italy. ⁴¹Department of Public Health, University Federico II of Naples, Naples, Italy. ⁴²Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. ⁴³Department of

Advanced Diagnostics, Fondazione IRCCS Istituto Tumori di Milano, University of Milan, Italy. ⁴⁴Laboratory of Clinical Biochemistry, Sant' Andrea University Hospital, Rome, Italy. ⁴⁵Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy. ⁴⁶Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ⁴⁷Department of Medicine and Surgery, Università Campus Bio-Medico, Rome, Italy. ⁴⁸Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. ⁴⁹Fondazione ReS, Rome, Italy.

G. Curigliano and P. Marchetti contributed equally to this article.

Corresponding Author: Sofia Verkhovskaia, Department of Oncology, IDI-IRCCS, Via dei Monti di Creta 104, Rome 00152, Italy. E-mail: sofiglia@gmail.com

Clin Cancer Res 2026;32:45–55

doi: 10.1158/1078-0432.CCR-25-0430

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

©2025 The Authors; Published by the American Association for Cancer Research

Patients and Methods

ROME trial

The ROME trial was a phase II, randomized, prospective, open label, multicenter clinical study that included patients ages 18 years or older with advanced or metastatic solid tumors that were inoperable, regardless of histology. The trial assessed patients with solid neoplasms in their second or third line of treatment and required next-generation sequencing profiling of tumor tissue (FoundationOne CDx) and blood samples (FoundationOne Liquid CDx). All patients were required to have measurable or evaluable disease as defined by the RECIST v1.1 or immune-related response criteria. Adequate renal, liver, and bone marrow functions were required at baseline. Additionally, patients with exclusively bone and/or brain metastases, uncontrolled brain disease (untreated and/or symptomatic), or those whose brain metastases had not been monitored for more than 2 months were excluded. Patients with concurrent severe and/or uncontrolled medical conditions that could compromise their participation in the study were also excluded.

Genomic information obtained from tumor tissue or liquid biopsy profiling was evaluated by an MTB panel of experts who provided guidance on TT for patients when actionable alterations were identified. Patients were then randomized 1:1 to receive either the TT as indicated by the MTB or the SoC therapy. TT encompassed targeted therapy or immunotherapy based on specific molecular targets. Crossover was permitted upon progression from the initial treatment received. Patients who were not randomized were classified as screening failures based on MTB decision.

MTB discussion

An MTB convened weekly to review every eligible patient. The MTB consisted of medical oncologists, pathologists, geneticists, immunologists, bioinformaticians, and other relevant specialists who reviewed each case, considering comprehensive molecular profiling data alongside the patient's clinical features, such as performance status, comorbidities, and concurrent treatments. The treating clinician presented each case, highlighting potential actionable therapeutic targets.

The pathogenicity of molecular alterations was evaluated using databases such as ClinVAR (RRID: SCR_006169), OncoKB (RRID: SCR_014782), and COSMIC (RRID: SCR_002260), and the ESMO ESCAT (European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets) was used to assess clinical actionability. The board used variant allele frequency thresholds of 1% for tissue biopsies and 2% for liquid biopsies.

MTB recommendations included randomizing patients to receive TT, referring them to a geneticist in the presence of somatic alterations with potential germline significance, modifying the SoC only when necessary, and suggesting early drug access programs, when available in Italy.

Tissue and liquid biopsies

A tissue sample obtained during the screening phase or within six months prior to enrollment was required for genomic testing. Samples collected within three months before the patient's informed consent form signature were acceptable, as were samples collected within 6 months, with prior confirmation by the MTB. No therapeutic interventions capable of altering the genomic profile or subclonal alterations were administered between the collection of

the tissue sample and the enrollment of the patients in the study. Archived tissue samples were accepted only for patients with glioblastomas and high-grade malignant gliomas to avoid another biopsy, even if there was an interval therapy. Patients with only one available biopsy—either liquid or solid—due to failure of one method during the screening phase remained eligible for inclusion and discussion in the MTB. Conversely, if both tissue and liquid biopsy characterizations failed, patients were classified as screening failures.

Genomic testing

For tissue biopsies, DNA was isolated from formalin-fixed, paraffin-embedded tumor tissue specimens using the DNAX extraction method and analyzed with FoundationOne CDx panel (324 genes) detecting substitutions, indels, copy-number alterations, gene rearrangements, microsatellite instability (MSI), and tumor mutational burden (TMB).

For liquid biopsies, circulating cell-free DNA was isolated from plasma, collected in FoundationOne Liquid CDx cell-free DNA blood collection tubes, and analyzed with the FoundationOne Liquid CDx panel (311 genes), detecting substitutions, insertions, indels in 311 genes, rearrangements in four genes, copy-number alterations in three genes, tumor fraction (TF), blood TMB, and MSI-H status.

Definition of concordance and discordance

Definition of subgroup stratification and concordance/discordance

In this exploratory study, genomic profiling results of all randomized patient were retrospectively reviewed. A CONSORT diagram was produced to show the population flowchart and the attrition rate (Fig. 1). Patients were stratified into three groups based on the mutational data sources:

1. **T + L group:** MTB recommended TT based on concordant alterations in both biopsies.
2. **T group:** MTB recommended TT based on tissue biopsy alteration alone (liquid biopsy failed/inconclusive or judged less informative).
3. **L group:** MTB recommended TT based on liquid biopsy alterations alone (tissue biopsy failed/unavailable or judged less informative).

Concordance was defined as identical actionable alterations in both biopsies, whereas discordance indicated clinically relevant alterations in only one biopsy type.

Study aim and statistical analysis

This analysis aimed to evaluate the impact of biopsy concordance or discordance on patient outcomes. Kaplan-Meier survival analysis was performed for overall survival (OS) and progression-free survival (PFS). χ^2 tests assessed categorical variable independence. Additionally, Cox proportional hazard models were used to estimate HRs for the effect of biopsy concordance on survival outcomes within relevant subgroups, including TF (low vs high with a threshold of 1% according to the FoundationOne Liquid CDx technical information) and number of metastatic sites (≤ 2 vs. > 2), and explore potential interaction effects. Due to the exploratory nature, statistical significance thresholds and power calculations were not predefined.




Figure 1. CONSORT diagram shows flow of patient selection for this exploratory analysis.

Ethical considerations

The trial adhered to the principles of the Declaration of Helsinki regarding research involving human subjects, received Institutional Review Board approval, and obtained written informed consent from all participants.

Protocol information: Clinical Trials Registry, NCT04591431.

Results

This exploratory analysis evaluated how MTB decisions based on tissue and liquid biopsy concordance/discordance influenced clinical outcomes in the ROME trial. Patient selection is depicted in the CONSORT diagram (Fig. 1), with baseline characteristics of concordant group summarized in Table 1 and concordant versus discordant in Table 2. The definitions of concordance groups (T + L) and discordance groups (T only or L only) are provided in the “Materials and Methods” section.

The overall concordance rate between tissue and liquid biopsies in MTB-indicated alterations was 49.2% (197 patients, T + L group), with actionable alterations found exclusively in tissue biopsies in 34.8% of cases (139 patients, T group) and exclusively in liquid biopsies in 16.0% (64 patients, L group). Among the 203 discordant cases, contributors included molecular alteration discrepancies (43%), discordant high TMB detection (35%), test failures (21%), and MSI mismatches (1%). Test failures occurred in 22 tissue and 20 liquid biopsies because of insufficient DNA (four cases), unsuccessful DNA extraction (one case), sample failure (two cases), biopsy failure (three cases), inadequate material (five cases), insufficient ctDNA (seven cases), brain primary tumors (eight cases), and other technical issues (12 cases).

Among the 91 molecularly discordant cases, alterations involved the *PTEN/PI3K/AKT/mTOR* pathway (50.5%), *FGF/FGFR* pathway (15.4%), *ERBB* (13.2%), and other pathways (20.9%). In concordant cases, prevalent alterations included TMB (23.9%), *PTEN/PI3K/AKT/mTOR* pathway (20.8%), *ERBB* pathway (19.8%), *FGF/FGFR* pathway (9.1%), MSI (8.1%), and other pathways (18.3%).

Patients with both T + L findings who received TT demonstrated improved survival outcomes compared with those

receiving SoC. In this group, 95 patients were randomized to TT and 102 to SoC. In the TT arm, the median OS was 10.89 versus 7.70 months in the SoC arm [HR = 0.76; 95% confidence interval (CI), 0.53–1.09; Fig. 2A], and the median PFS was 4.90 versus 2.80 months (HR = 0.56; 95% CI, 0.41–0.77; Fig. 2B), respectively. Additionally, the 9-month OS rate was 54.50% in the TT group and 46.80% in the SoC group, whereas the 12-month OS rate was 47.10% and 38.80%, respectively. For PFS, the 9- and 12-month rates were 33.90% and 26.60% in the TT arm compared with 13.70% and 9.10% in the SoC arm, respectively. Among T + L patients, the objective response rate (ORR) was 22.1% in the TT arm versus 12.8% in the SoC arm.

Distinctively, among patients whose treatment decisions were guided exclusively by tissue biopsy findings (T group), 71 were randomized to TT and 68 to SoC. The median OS was 9.93 months in the TT arm and 10.03 months in the SoC arm (HR = 1.14; 95% CI, 0.73–1.78; Supplementary Fig. S1). In this group, the 12-month OS rates were 41.1% for TT and 47.6% for SoC. The median PFS was 3.06 months in the TT group versus 2.99 months in the SoC group (HR = 0.81; 95% CI, 0.56–1.17; Supplementary Fig. S2), with 12-month PFS rates of 19.70% and 10.10%, respectively. The ORR in the T-only group was 12.7% in the TT arm versus 5.9% in the SoC arm.

Finally, 34 and 30 patients in the L group were randomized to receive TT and SoC, respectively. The median OS was 4.05 months for TT versus 3.49 months for SoC (HR = 1.10; 95% CI, 0.63–1.92; Supplementary Fig. S3), and the median PFS was 2.07 versus 2.32 months (HR 0.78; 95% CI: 0.46–1.32; Supplementary Fig. S4), respectively. The 9-month OS rate was 36.60% in the TT group versus 30.00% in the SoC group, whereas the 12-month OS rate was 16.50% versus 26.70%, respectively. The 9-month PFS rate was 17.50% in the TT arm compared with 3.30% in the SoC arm, whereas the 12-month PFS rate was 14.00% in the TT arm, and all patients treated with SoC progressed (0%). In this group, the ORR was 14.7% in the TT group versus 10% in the SoC group.

To specifically assess the magnitude of benefit conferred by the TT relative to the modality through which actionable genomic

Table 1. Patient characteristics in the concordant group.

Characteristics	Overall	SoC	TT
	N = 197 (%)	N = 102 (%)	N = 95 (%)
Age (years)			
Median (range)	61 (36-85)	60 (37-84)	63 (36-85)
Gender			
Male	83 (42.1%)	48 (47.1%)	35 (36.8%)
Female	114 (57.9%)	54 (52.9%)	60 (63.2%)
Ethnicity			
Caucasian	193 (98%)	100 (98%)	93 (97.8%)
Oriental	1 (0.5%)	0	1 (1.1%)
Hispanic	1 (0.5%)	1 (1%)	0
Afro-American	0	0	0
Other	1 (0.5%)	0	1 (1.1%)
Not available	1 (0.5%)	1 (1%)	0
Primary tumor			
Breast	24 (12.2%)	10 (9.8%)	14 (14.7%)
Gastrointestinal	59 (30%)	35 (34.3%)	24 (25.3%)
Non-small cell lung cancer	17 (8.6%)	8 (7.8%)	9 (9.5%)
Other	97 (49.2%)	49 (48%)	48 (50.5%)
Eastern Cooperative Oncology Group performance status			
0	120 (60.9%)	63 (61.8%)	57 (60%)
1	77 (39.1%)	39 (38.2%)	38 (40%)
2	0	0	0
No. of metastatic sites			
≤2	109 (55.3%)	54 (53.0%)	55 (57.9%)
>2	78 (39.6%)	40 (39.2%)	38 (40.0%)
Not available	10 (5.1%)	8 (7.8%)	2 (2.1%)

alterations were detected, we report separately a comparative analysis among T + L, T, and L groups focusing exclusively on patients in the TT arm. By isolating the TT arm, we aimed to directly evaluate how the comprehensive or limited detection of actionable alterations through these different biopsy approaches influenced survival outcomes. The median OS was 10.89 months in the T + L group, compared with 9.93 months in the T group and 4.05 months in the L group (**Fig. 3A**). Similarly, the median PFS was 4.90 months in the T + L group, versus 3.06 months in the T group and 2.07 months in the L group (**Fig. 3B**). The 12-month OS rates were 47.10% for the T + L group, 41.10% for the T group, and 16.50% for the L group, whereas the 12-month PFS rates were 26.60%, 19.70%, and 14.00%, respectively.

Survival outcomes were further examined by categorizing patients based on whether tissue and liquid biopsies provided concordant (T + L) or discordant (T or L) results for the specific genomic alteration that informed the therapeutic target proposed for TT. One hundred and ninety-seven (49.2%) patients had concordant tests. In comparison, 161 (40.3%) patients were discordant due to the absence of the alteration in one of the samples, and 42 (10.5%) patients were discordant due to tissue or liquid test failure. Among patients with concordant findings ($n = 95$ in the TT arm, $n = 102$ in the SoC arm), those receiving TT showed improved outcomes compared with those receiving SoC, as already shown in **Fig. 2**. In contrast, patients with available but discordant molecular results ($n = 88$ in the TT arm, $n = 73$ in the SoC arm) experienced less benefit from TT. In the TT arm, the median OS for discordant cases was 7.34 months compared with 8.49 months in the SoC arm (HR = 1.21; 95% CI, 0.81-1.79; Supplementary Fig. S5). Similarly, the median PFS

in the TT arm was 2.86 months compared with 2.93 months in the SoC arm (HR = 0.87; 95% CI, 0.62-1.23; Supplementary Fig. S6). The 9-month OS rate in discordant TT patients was 44.90%, and the 12-month OS rate was 32.00% compared with 47.10% and 41.70%, respectively, in the SoC group. For PFS, the 9- and 12-month rates were 23.20% and 17.70% in the TT arm compared with 16.90% and 9.40% in the SoC arm. In discordant group, the ORR was 12.5% in the TT arm versus 6.9% in the SoC arm.

The comparative analysis of concordant, true discordant, and discordant due to failure groups, conducted exclusively in patients randomized to TT as recommended by the MTB, demonstrated that those with concordant biopsy results experienced the most considerable benefit, achieving notably longer survival outcomes. In the TT arm, the median OS was the highest in the concordant group (10.89 months), followed by the failure discordant (10.39 months) and true discordant groups (7.34 months) (**Fig. 4A**). The median PFS was the longest in the concordant group (4.90 months), followed by the true discordant (2.86 months) and failure discordant groups (2.53 months) (**Fig. 4B**). The 12-month OS rates for the concordant, failure discordant, and true discordant groups were 47.10%, 41.20%, and 32.00%, respectively, whereas the 12-month PFS rates were 26.60%, 17.60%, and 17.70%, respectively.

To further investigate concordance rates, an analysis was conducted based on TF, the number of metastatic sites, and the location of both the site of genomic profilation and the primary tumor.

A total of 317 patients with detectable TF were identified, revealing a higher concordance rate when TF was high compared with

Table 2. Patient characteristics in concordant versus discordant groups.

Characteristics	Overall	Concordant (T + L)	Discordant (T or L)
	N = 400 (%)	N = 197 (%)	N = 203 (%)
Age (years)			
Median (range)	61 (22–85)	61 (36–85)	61 (22–83)
Gender			
Male	192 (48.0%)	83 (42.1%)	109 (53.7%)
Female	208 (52.0%)	114 (57.9%)	94 (46.3%)
Ethnicity			
Caucasian	392 (98.0%)	193 (98.0%)	199 (98.0%)
Oriental	2 (0.5%)	1 (0.5%)	1 (0.5%)
Hispanic	3 (0.7%)	1 (0.5%)	2 (1.0%)
Afro-American	1 (0.3%)	0	1 (0.5%)
Other	1 (0.3%)	1 (0.5%)	0
Not available	1 (0.3%)	1 (0.5%)	0
Primary tumor			
Breast	40 (10.0%)	24 (12.2%)	16 (7.9%)
Gastrointestinal	109 (27.2%)	59 (30.0%)	50 (24.6%)
Non-small cell lung cancer	31 (7.8%)	17 (8.6%)	14 (6.9%)
Other	220 (55.0%)	97 (49.2%)	123 (60.6%)
Eastern Cooperative Oncology Group performance status			
0	237 (59.2%)	120 (60.9%)	117 (57.6%)
1	162 (40.5%)	77 (39.1%)	85 (41.9%)
2	1 (0.3%)	0	1 (0.5%)
No. of metastatic sites			
≤2	255 (63.7%)	109 (55.4%)	146 (71.9%)
>2	128 (32.0%)	78 (39.6%)	50 (24.6%)
Not available	17 (4.3%)	10 (5.0%)	7 (3.5%)

non-high TF (62.4% vs. 43%; χ^2 *P* value <0.001). By excluding patients whose profiling tests failed and those with primary brain tumors, the concordance rate (T + L) increased to 70.1% for high TF compared with 44.6% for non-high TF (χ^2 *P* value <0.0001). Additionally, a subanalysis was performed, excluding patients whose MTB decision was based on TMB values or MSI. This refined analysis focused solely on patients for whom treatment decisions relied on molecular alterations. Under these conditions, concordance rates further increased to 88.6% for high TF and 58.6% for non-high TF (χ^2 *P* value <0.0001). Interaction analysis of OS among concordant patients treated with TT versus SoC, stratified by TF, demonstrated HRs of 0.64 (95% CI, 0.31–1.29) for patients with low TF and 0.89 (95% CI, 0.56–1.43) for those with high TF. Similarly, PFS benefits in this subgroup were confirmed through interaction analysis, yielding HRs of 0.50 (95% CI, 0.28–0.88) for patients with low TF and 0.60 (95% CI, 0.39–0.91) for those with high TF. In T- and L-only subgroups, HRs were in line with HR evaluated without interaction stratification, not showing differences on outcomes across TF strata.

For the number of metastatic sites, patients were divided into two groups (≤2 sites vs. >2 sites). The concordance rate was higher in patients with one or two sites (55.4%) than in those with more than two sites (39.6%). In the combined T + L subgroup, the comparison of TT versus SoC yielded OS HRs of 0.81 (95% CI, 0.50–1.31) for patients with ≤2 sites and 0.68 (95% CI, 0.39–1.20) for those with >2 sites. Similarly, PFS HRs were 0.52 (95% CI, 0.34–0.79) for patients with ≤2 sites and 0.63 (95% CI, 0.39–1.01) for those with >2 sites. Interaction analysis of OS by metastatic site count in the “T-only” and “L-only” subgroups did not differ significantly from the HR evaluated without interaction strata. Regarding the

sites of primary tumor and solid tissue samples used for genomic profiling, the concordance rate was assessed using the stratified χ^2 test (Supplementary Figs. S7 and S8).

To assess whether some discordant results were because of differences in variant coverage between the two tests, we generated a Venn diagram (Supplementary Fig. S9) illustrating the alterations covered by both assays or by only one of them. Whereas all therapeutic target genes with full exonic coverage were included in both panels, the FoundationOne CDx panel encompassed a greater number of genes with select intronic region coverage, thereby enabling more accurate detection of rearrangements. Nevertheless, the proportion of patients who received a treatment indication based on rearrangements in genes with intronic coverage by FoundationOne CDx was low (19/400, 4.8%, 12 patients assigned to the TT arm and 7 to the SoC arm). In 17 of 18 patients who underwent both tests, the rearrangement was detected by both assays, whereas in only one case it was identified in the tissue sample but not in the liquid biopsy.

Discussion

This exploratory analysis of the ROME trial highlights the complementary roles of tissue and liquid biopsy profiling in guiding molecularly tailored treatments and underscores the impact of concordance between these modalities on clinical outcomes. The study provides insights into the predictive value of integrating these diagnostic approaches in advanced solid tumors by evaluating concordant and discordant biopsy results.

The ROME trial, which utilized extensive next-generation sequencing on tissue samples, collected primarily at progression, and ctDNA from liquid biopsies, provided a unique opportunity to




Figure 2.

OS and PFS probability in patients with concordant tissue and liquid biopsy results (T + L group). The blue line represents patients receiving SoC (arm A, $n = 102$), whereas the red line represents patients receiving TT (arm B, $n = 85$). **A**, The median OS was 7.70 months in arm A versus 10.89 months in arm B (HR = 0.76, 95% CI, 0.53–1.09). **B**, The median PFS was 2.80 versus 4.90 months in arm A versus arm B (HR = 0.56; 95% CI, 0.41–0.77).

evaluate dual-source genomic information's impact on MTB decisions and clinical outcomes. During the MTB discussion, TT was proposed based on alterations detected in both biopsies in 49.2% of cases, whereas actionable alterations were identified exclusively in tissue biopsies in 35% of cases and in liquid biopsies in 16%. This indicates that nearly half of therapeutic decisions relied on concordant data from both modalities, whereas the remaining depended on one test alone. Concordance and discordance were assessed basing only on mutations considered actionable after MTB review—a novel approach to defining these terms.

The observed concordance rate (49.2%) is lower than in literature reports, attributable to multiple factors (18). First, certain genomic alterations are more detectable in tissue or liquid biopsies due to biological properties. Low ctDNA shedding in some tumors reduces liquid biopsy sensitivity, whereas liquid biopsies better capture tumor heterogeneity (19, 20). TMB concordance is generally lower than for individual molecular alterations, with liquid biopsies often reporting higher TMB levels. Amplifications, for example, are more reliably detected in tissue samples (21, 22). Test failure (approximately 20% of cases) further contributed to the observed discordance.

When revising differences in variant coverage between the liquid and tissue profiling by Venn diagram (Supplementary Fig. S10), we can assume that differences in coverage did not significantly affect our concordance analysis.

In our study, concordance rates between liquid and tissue biopsies were markedly higher in cases with elevated ctDNA TF, especially after excluding technical failures and primary brain tumors. Under these conditions—and when considering specific genomic alterations rather than broad biomarkers like TMB or MSI—our concordance rates approach the values reported in the literature (23), although they remain slightly lower. We believe this discrepancy stems from our stricter definition of concordance: whereas most studies count any shared mutation between tissue and plasma as concordant, we only score concordance when the identical actionable mutation is present in both sample types. Notably, primary brain tumors ($\approx 10\%$ of our cohort) showed especially high discordance, which further reduced the overall concordance rate (see Supplementary Fig. S8).

These findings emphasize the utility of dual biopsy data to propose a TT, even when actionable information derives from one modality, underscoring their integration's value in precision oncology. An aspect not evaluated in this study concerns the possibility of performing liquid biopsy not only on blood but also on other biological fluids, such as cerebrospinal fluid (for brain tumors), ascitic fluid, or pleural fluid for specific disease localizations, in which blood might prove to be an unreliable source of relevant genomic alterations.

Although recent studies suggest that ctDNA positivity is significantly correlated with poorer outcomes across various cancer types, confirming its prognostic significance (24, 25), its ability to predict response to a targeted therapy in patients harboring specific actionable genomic alterations in both tissue and liquid biopsies remains less established.

In our study, the most meaningful clinical benefit of TT compared with SoC was observed in the T + L group. The 12-month OS rate in this group approached 50% (47.10%), further emphasizing the robust benefit derived from concordant findings. The presence of actionable alterations in both tissue and liquid biopsies may indicate a central role for these alterations in driving tumor progression, making them particularly effective therapeutic targets. This finding could also reflect the biological dominance of these alterations, representing critical driver events that are consistently detectable across multiple biopsy modalities. Furthermore, the concordance of results may suggest a more stable and homogeneous tumor biology in these patients, which might enhance the efficacy of TT. Finally, the availability of dual-source data likely enhanced the confidence of the MTB in identifying actionable targets, resulting in more precise therapeutic recommendations.

The uncertain benefit observed in the T-only group (median OS of 9.93 months with TT vs. 10.03 months with SoC; HR = 1.14; median PFS of 3.06 months with TT vs. 2.99 months with SoC; HR = 0.81) underscores the challenges of relying exclusively on tissue biopsies. Tissue sampling, although providing detailed histologic and molecular information, is inherently limited in capturing intratumoral heterogeneity and dynamic molecular changes over time. These findings suggest that additional molecular data




Figure 3. Kaplan-Meier curves showing OS and PFS probability stratified by concordance status in the TT arm. Blue line, patients with concordant tissue and liquid biopsies (T + L group, $n = 95$). Red line, patients with tissue biopsy only (T group, $n = 71$). Green line, patients with liquid biopsy only (L group, $n = 34$). **A**, The median OS was 10.89 months in the T + L group, compared with 9.93 months in the T group and 4.05 months in the L group. The 12-month OS rates were 47.10% for T + L, 41.10% for T, and 16.50% for L, respectively. **B**, The median PFS was 4.90 months in the T + L group versus 3.06 months in the T group and 2.07 months in the L group. The 12-month PFS rates were 26.60%, 19.70%, and 14.00% in the T + L, T, and L groups, respectively.

from liquid biopsies may enhance treatment precision in this subgroup.

The results of the L subgroup, given the limited number of patients, should be interpreted with caution. The poor outcomes in this subgroup could reflect a higher tumor burden, as indicated by the detectability of ctDNA in liquid biopsies. Additionally, the generally lower OS and PFS observed in this subgroup compared with others support the need for further exploration of these patients' unique molecular and clinical characteristics. Alternatively, it may point to technical limitations of current liquid biopsy technologies, such as reduced sensitivity in detecting alterations from

nonshedding tumors. These observations highlight the importance of refining liquid biopsy methodologies to improve their sensitivity and reliability. Additionally, interpreting liquid biopsy findings within the broader clinical and molecular context is essential to ensure accurate therapeutic decisions, particularly in cases in which actionable alterations are detected exclusively in liquid biopsies.

Furthermore, the comparative analysis of concordant versus discordant biopsy results revealed interesting differences in survival outcomes. Patients with concordant findings demonstrated better OS and PFS with TT compared with SoC, whereas those with discordant results showed less pronounced benefits from TT. The concordant




Figure 4. Kaplan-Meier curves showing (A) OS and (B) PFS in patients receiving TT, stratified by specific genomic alteration concordance status. The blue line represents patients with discordant results due to test failure (group 1, $n = 17$), the red line patients with true discordant results (group 2, $n = 88$), and the green line patients with concordant results (group 3, $n = 95$). Median OS: 10.89 months in group 3 versus 10.39 in group 1 and 7.34 in group 2. Median PFS: 4.90 months in the concordant group, followed by the true discordant group (2.86 months) and failure discordant group (2.53 months). Disc., discordant.

group's 12-month OS rate of 47.1% compared with 32.0% in the true discordant group reinforces the potential of concordance as a predictive biomarker for therapeutic efficacy. This suggests that integrating both tissue and liquid biopsy results may help identify patients most likely to benefit from tailored therapies.

Subgroup analyses were conducted to assess whether the prognostic impact of tissue-liquid biopsy concordance varied by TF (low vs. high) and metastatic burden (≤ 2 vs. > 2 sites). A consistent survival benefit was observed for patients with concordant profiling (T + L) compared with discordant profiling (T only or L only) across both TF strata and levels of metastatic involvement. In both TF-low and TF-high subgroups, HRs for OS and PFS favored the concordant group, with overlapping CIs and no significant interaction effects. Likewise, the survival advantage of the T + L group was maintained irrespective of the number of metastatic sites, with no evidence of effect modification. These findings indicate that the predictive value of tissue-liquid biopsy concordance is robust and not affected by tumor DNA shedding or disease extent. Additionally, we observed that high discordance rates in actionable alterations involving the PI3K/PTEN/AKT/mTOR and ERBB2 pathways highlight the molecular complexity and spatial heterogeneity of these signaling networks. For ERBB2, this may partly stem from the technical limitations of liquid biopsies in detecting gene amplifications, which are more reliably identified in tissue samples (22). Additionally, the dynamic nature of signaling in these pathways and their frequent involvement in tumor heterogeneity may contribute to discordance (26, 27). This underscores the need for combining tissue and liquid biopsies to obtain a more comprehensive molecular profile, particularly when targeting these pathways. Additional strategies, such as repeat biopsies, advanced bioinformatics tools, or complementary diagnostic modalities, may be required for patients with discordant results to refine treatment selection and improve outcomes. Our findings have several important implications for clinical practice and future research. They support the integration of both tissue and liquid biopsy profiling as a viable approach in molecular diagnostics and highlight the potential of concordance between biopsy modalities as a stratification factor in clinical trials evaluating molecularly guided therapies. Finally, they underscore the need for prospective validation of these findings and the development of strategies to address discordance, such as incorporating additional molecular profiling methods or enhancing the sensitivity and specificity of existing technologies.

Several limitations of this study should be acknowledged. The exploratory nature of the analysis and the absence of predefined statistical power for subgroup comparisons limit the generalizability of the findings. The high rate of test failures (~20% of discordant cases) and small sample size in some subgroups (especially liquid-only subgroups) could affect robustness of subgroup analyses. Discordance due to tumor heterogeneity, technical limitations in detecting amplifications, low ctDNA shedding, and challenges in specific tumor types (notably brain tumors) need to be interpreted. The temporal proximity of tissue and liquid biopsy collection in this study minimizes the likelihood that discordance is attributable to tumor evolution over time, suggesting that other factors, such as biological and technical differences, may play a more significant role.

Future studies should focus on prospectively validating concordance as a biomarker for therapeutic success and exploring the integration of additional diagnostic modalities to address discordance. Advances in liquid biopsy technologies and bioinformatics

are likely to further enhance the precision of molecular profiling, ultimately improving outcomes for patients with advanced solid tumors. By addressing the challenges of discordance and leveraging the strengths of both biopsy modalities, future strategies can refine precision oncology algorithms and enhance clinical outcomes for patients with advanced cancers.

Data Availability

The authors confirm that the data supporting the findings of this study are accessible within the article and its Supplementary material. The results of FoundationOne CDx and FoundationOne Liquid CDx analyses supporting the findings of this study can be obtained from the corresponding author upon reasonable request.

Authors' Disclosures

C. Cremolini reports grants and personal fees from Roche, Servier, Bayer, Takeda, Pierre Fabre, and Merck Serono; grants from Tempus and Pfizer; and personal fees from AbbVie, Amgen, Nordic Pharma, MSD, Bristol Myers Squibb, Rottapharm Biotech, Revolution Medicines, Bicara Therapeutics, and Johnson & Johnson outside the submitted work. S. Scagnoli reports personal fees from Pfizer, Eli Lilly, Novartis, Daiichi Sankyo, AstraZeneca, Roche, and Sophos and personal fees and other support from Gilead during the conduct of the study. S. Lonardi reports personal fees from Amgen, Merck Serono, Eli Lilly, Servier, AstraZeneca, Incyte, Daiichi Sankyo, Bristol Myers Squibb, MSD, Astellas Pharma, Bayer, Takeda, Rottapharm Biotech, BeiGene, Helion, Nimbus Therapeutics, Fosun Pharma, Roche, Pierre Fabre, GSK, MSD Oncology, and Incyte and other support from Amgen, Merck Serono, Bayer, Roche, Eli Lilly, AstraZeneca, and Bristol Myers Squibb outside the submitted work. L. Fornaro reports personal fees from AstraZeneca, MSD, Daiichi Sankyo, Servier, Bristol Myers Squibb, Taiho Oncology, BeiGene, Astellas, Incyte, and Eli Lilly and nonfinancial support from Servier and Merck outside the submitted work. V. Guarneri reports grants and personal fees from Eli Lilly, AstraZeneca, Roche, Pfizer, MSD, Gilead, Menarini Stemline, and Daiichi Sankyo; personal fees from Novartis and Exact Sciences; and grants from Bristol Myers Squibb and Merck outside the submitted work. U. De Giorgi reports personal fees from Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, and Pfizer outside the submitted work. P.A. Ascierto reports grants and personal fees from Bristol Myers Squibb, Roche Genentech, Regeneron, and Medicenna; personal fees and other support from MSD, Pierre Fabre, Bio AI Health, Replimune, and Phlogem; grants, personal fees, and other support from Pfizer; nonfinancial support from ValoTx; and personal fees from Novartis, Sun Pharma, Immunocore, Italfarmaco, Boehringer Ingelheim, Nouscom, Bayer, Erasca, BioNTech, Anaveon, Genmab, Menarini, Incyte, and Imcheck Therapeutics outside the submitted work. G. D'Amati reports personal fees and other support from Roche and personal fees, nonfinancial support, and other support from MSD, AstraZeneca, and Eli Lilly outside the submitted work. S. Pisegna reports personal fees from Eli Lilly, Daiichi Sankyo, AstraZeneca, Pfizer, Novartis, and Gilead outside the submitted work. S. Verkhovskaia reports personal fees from Novartis outside the submitted work. R. Bordonaro reports grants and personal fees from AstraZeneca, Novartis, Pfizer, Roche, Janssen, Bristol Myers Squibb, and Sanofi outside the submitted work. L. Del Mastro reports grants and personal fees from Eli Lilly, Novartis, Seagen, Pierre Fabre, Pfizer, and MSD; grants, personal fees, and nonfinancial support from Roche, Daiichi Sankyo, AstraZeneca, Gilead, and Menarini Stemline; and personal fees from Olema, Exact Sciences, Eisai, Ipsen, and GSK outside the submitted work. F. Puglisi reports grants, personal fees, and other support from AstraZeneca, Eli Lilly, and Roche; personal fees and other support from Daiichi Sankyo, Gilead, Menarini, MSD, Novartis, and Pfizer; grants from Eisai; and personal fees from Exact Sciences, Italfarmaco, and Pierre Fabre outside the submitted work. A. Zambelli reports personal fees and nonfinancial support from Roche, AstraZeneca, and Daiichi Sankyo; grants and personal fees from Pfizer; and personal fees from Gilead, Eli Lilly, Novartis, Exact Sciences, Menarini Stemline, and MSD outside the submitted work. D. Marino reports other support from Merck and Amgen and nonfinancial support and other support from AstraZeneca outside the submitted work. F. Cappuzzo reports personal fees from Roche, AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati Therapeutics, Galecto, Ose Immunotherapeutics, Illumina, Thermo Fisher Scientific, BeiGene, AbbVie, Summit Therapeutics, and MSD outside the submitted work. U. Malapelle reports personal fees from

Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, Diaceutics, GSK, Merck, AstraZeneca, Janssen, Diatch, Novartis, Hedera, and Menarini outside the submitted work. G. Pruneri reports grants and personal fees from Roche and personal fees from Illumina, Thermo Fisher Scientific, Eli Lilly, Novartis, AstraZeneca, Menarini, and ADS Biotec outside the submitted work. G. Tonini reports other support from PharmaMar, Molteni, Novartis, and MSD outside the submitted work. G. Curigliano reports personal fees from Roche, Daichii Sankyo, Eli Lilly, Novartis, Pfizer, Menarini, Gilead, AstraZeneca, and Exact Sciences outside the submitted work. P. Marchetti reports grants from Novartis, Roche, Eli Lilly, Merck Serono, Incyte, Takeda, Pfizer, Bristol Myers Squibb, and Menarini Stemline during the conduct of the study as well as personal fees from Amgen, Astellas, Bayer, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, and TomaLab outside the submitted work; in addition, P. Marchetti is the Founder and Chairman or President of AISCUP, a Patients' Association, Fondazione per la Medicina Personalizzata, Foundation for Personalized Medicine, a national independent health and social care charity. No disclosures were reported by the other authors.

Authors' Contributions

A. Botticelli: Conceptualization, data curation, supervision, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing. **C. Cremolini:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **S. Scagnoli:** Supervision, validation, investigation, visualization, methodology, writing—original draft, writing—review and editing. **M. Biffoni:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **S. Lonardi:** Data curation, validation, investigation, visualization, writing—review and editing. **L. Fornaro:** Data curation, validation, investigation, visualization, writing—review and editing. **V. Guarneri:** Data curation, validation, investigation, visualization, writing—review and editing. **U. De Giorgi:** Data curation, validation, investigation, visualization, writing—review and editing. **P.A. Ascierto:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **G. Blandino:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **G. D'Amati:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **M. Aglietta:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **P. Conte:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **E. Crimini:** Supervision, validation, investigation, visualization, methodology, writing—original draft, writing—review and editing. **M. Ceracchi:** Data curation, software, formal analysis, supervision, validation, investigation, visualization, methodology, writing—review and editing. **S. Pisegna:** Supervision, validation, investigation, visualization, methodology, writing—original draft, writing—review and editing. **S. Verkhovskaia:** Supervision, validation, investigation, visualization, methodology, writing—original draft, writing—review and editing. **R. Bordonaro:** Data curation, validation, investigation, visualization, writing—review and editing. **S. Bracarda:** Data curation, validation, investigation, visualization, writing—review and editing. **G. Butturini:** Data curation, validation, investigation, visualization, writing—review and editing. **L. Del Mastro:** Data curation, validation, investigation, visualization, writing—review and editing. **A. DeCensi:** Data curation, validation, investigation, visualization, writing—review and editing. **A. Fabbri:** Data curation, validation, investigation, visualization, writing—review and editing. **E. Fenocchio:** Data curation, validation, investigation, visualization, writing—review and editing. **S. Gori:** Data curation, validation, investigation, visualization, writing—review and editing. **G. Metro:** Data curation, validation, investigation, visualization, writing—review and editing. **A. Pessino:** Data curation, validation, investigation, visualization, writing—review and editing. **D. Pozzessere:** Data curation,

validation, investigation, visualization, writing—review and editing. **F. Puglisi:** Data curation, validation, investigation, visualization, writing—review and editing. **S. Tamberi:** Data curation, validation, investigation, visualization, writing—review and editing. **A. Zambelli:** Data curation, validation, investigation, visualization, writing—review and editing. **D. Marino:** Data curation, validation, investigation, visualization, writing—review and editing. **E. Capoluongo:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **F. Cappuzzo:** Conceptualization, data curation, supervision, validation, investigation, visualization, methodology, writing—review and editing. **B. Cerbelli:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **G. Giannini:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **U. Malapelle:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **F. Mazza:** Data curation, validation, investigation, visualization, writing—review and editing. **M. Nuti:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **G. Pruneri:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **M. Simmaco:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **L. Strigari:** Data curation, software, formal analysis, supervision, validation, investigation, visualization, methodology, writing—review and editing. **G. Tonini:** Conceptualization, data curation, formal analysis, funding acquisition, validation, investigation, visualization, writing—review and editing. **N. Martini:** Conceptualization, supervision, validation, investigation, visualization, methodology, writing—review and editing. **G. Curigliano:** Conceptualization, data curation, supervision, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing. **P. Marchetti:** Conceptualization, resources, data curation, supervision, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing.

Acknowledgments

Erlotinib, pertuzumab, vemurafenib, trastuzumab emtansine, alectinib, vismodegib, cobimetinib, atezolizumab, trastuzumab, ipatasertib (GDC-0068), entrectinib, and pralsetinib were provided by Roche; everolimus, lapatinib, and apaltesib were provided by Novartis; palbociclib and talazoparib were provided by Pfizer; ipilimumab and nivolumab were provided by Bristol Myers Squibb; brigatinib was provided by Takeda Pharmaceuticals; ponatinib, itacitinib (INCB039110), and pemigatinib (INCB054828) were provided by Incyte; selpercatinib was provided by Eli Lilly; and tepotinib was provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). Next-generation sequencing test FoundationOne CDx and FoundationOne Liquid CDx were provided by Foundation Medicine, Inc. This study was supported through unrestricted grants provided by Roche, Takeda, Bristol Myers Squibb, Pfizer, Incyte, and Eli Lilly. These contributions were regulated by contractual agreements with the study sponsor, the Fondazione per la Medicina Personalizzata (FMP). The funding entities had no role in the study design, data collection, analysis, interpretation, or manuscript preparation.

Note

Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Received February 4, 2025; revised April 16, 2025; accepted August 15, 2025; posted first August 20, 2025.

References

- Pankiw M, Brezden-Masley C, Charames GS. Comprehensive genomic profiling for oncological advancements by precision medicine. *Med Oncol* 2023;41:1.
- Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. *Cell* 2024;187:1617–35.
- Jin J, Wu X, Yin J, Li M, Shen J, Li J, et al. Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy. *Front Oncol* 2019;9:263.
- Chakravarty D, Solit DB. Clinical cancer genomic profiling. *Nat Rev Genet* 2021;22:483–501.
- Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. *Mol Cancer* 2022;21:79.
- Teuwen L-A, Roets E, D'Hoore P, Pauwels P, Prenen H. Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: the experience of an academic hospital. *Diagnostics* 2023;13:1619.
- Halim FS, Baskoro BA, Azhar Y, Prasetyo PD, Utomo ARH, Panigoro SS. Recent development of biopsy techniques on solid tumor and its relevance in solid tumor management. 2024:273–312.

8. Pinzani P, D'Argenio V, Del Re M, Pellegrini C, Cucchiara F, Salvianti F, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. *Clin Chem Lab Med (Cclm)* 2021;59: 1181–200.
9. Allen TA. The role of circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance. *Cancers (Basel)* 2024;16:1377.
10. Ciardiello D, Boscolo Bielo L, Napolitano S, Martinelli E, Troiani T, Nicastro A, et al. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF^{V600E} wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. *Ann Oncol* 2024;35:1105–15.
11. Ding H, Yuan M, Yang Y, Xu XS. Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy. *NPJ Precis Oncol* 2025;9:5.
12. Martínez-Vila C, Teixido C, Aya F, Martín R, González-Navarro EA, Alos L, et al. Detection of circulating tumor DNA in liquid biopsy: current techniques and potential applications in melanoma. *Int J Mol Sci* 2025;26:861.
13. Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. *Signal Transduct Target Ther* 2024;9:336.
14. Vanni I, Pastorino L, Andreotti V, Comandini D, Fornarini G, Grassi M, et al. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort. *J Transl Med* 2024;22:462.
15. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. *Genome Med* 2020;12:8.
16. Larson KL, Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, et al. Clinical outcomes of molecular tumor boards: a systematic review. *JCO Precis Oncol* 2021;1:122–32.
17. Botticelli A, Scagnoli S, Conte P, Cremolini C, Ascierto PA, Cappuzzo F, et al. LBA7 The Rome trial from histology to target: the road to personalize targeted therapy and immunotherapy. *Ann Oncol* 2024;35:S1202.
18. Jahangiri L, Hurst T. Assessing the concordance of genomic alterations between circulating-free DNA and tumour tissue in cancer patients. *Cancers (Basel)* 2019;11:1938.
19. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med* 2012;366:883–92.
20. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. *Genome Biol* 2014;15:453.
21. Arshadi A, Tolomeo D, Venuto S, Storlazzi C. Advancements in focal amplification detection in tumor/liquid biopsies and emerging clinical applications. *Genes (Basel)* 2023;14:1304.
22. Xie S, Wang Y, Gong Z, Li Y, Yang W, Liu G, et al. Liquid biopsy and tissue biopsy comparison with digital PCR and IHC/FISH for HER2 amplification detection in breast cancer patients. *J Cancer* 2022;13:744–51.
23. Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, et al. Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation. *Clin Cancer Res* 2024;30:2452–60.
24. Crippa A, Laere BD, Discacciati A, Larsson B, Persson M, Johansson S, et al. Prognostic value of the circulating tumor DNA fraction in metastatic castration-resistant prostate cancer: results from the ProBio platform trial. *Eur Urol Oncol* 2025.
25. Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. *Ann Oncol* 2018;29:490–6.
26. Kwan EM, Dai C, Fettke H, Hauser C, Docanto MM, Bukczynska P, et al. Plasma cell-free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer. *JCO Precis Oncol* 2021;6:22–37.
27. Del Re M, Crucitta S, Lorenzini G, De Angelis C, Diodati L, Cavallero D, et al. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. *Pharmacol Res* 2021;163:105241.